Literature DB >> 26428541

Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis.

Yazan Migdady1, Mohammed Salhab2,3, Nam H Dang1, Merry J Markham1, Adam J Olszewski3,4.   

Abstract

We evaluated the association of baseline prognostic factors with conditional net survival among survivors of six subtypes non-Hodgkin lymphoma using the SEER program data from 2000-2012. Among 2-year survivors, further prognosis markedly improved in Burkitt's (BL) and diffuse large B-cell lymphoma (DLBCL), and became the same as for follicular lymphoma (5-year net survival ≥ 85%). Mantle cell lymphoma (MCL) demonstrated the worst prognosis of all studied histologies up to 5 years of survivorship. Age and stage lost prognostic significance in BL within 2 years from diagnosis. Racial disparities in net survival disappeared within 2 years for all subtypes, except in chronic lymphocytic leukemia, where black patients had persistently worse prognosis, and in MCL, where they had unexpectedly better prognosis than other races after 2 years. Many baseline factors may lose their initial prognostic value for lymphoma survivors, which should be considered when counseling patients about their prognosis and long-term surveillance.

Entities:  

Keywords:  Burkitt lymphoma; conditional survival; diffuse large B-cell lymphoma; epidemiology; non-Hodgkin lymphoma; relative survival

Mesh:

Year:  2015        PMID: 26428541     DOI: 10.3109/10428194.2015.1102246

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Conditional relative survival among patients with follicular lymphoma: a population-based study in the Netherlands.

Authors:  Manette A W Dinnessen; Otto Visser; Sanne H Tonino; Eduardus F M Posthuma; Nicole M A Blijlevens; Marie José Kersten; Pieternella J Lugtenburg; Avinash G Dinmohamed
Journal:  Blood Cancer J       Date:  2021-01-13       Impact factor: 11.037

2.  Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy.

Authors:  Shintaro Narita; Kyoko Nomura; Shingo Hatakeyama; Masahiro Takahashi; Toshihiko Sakurai; Sadafumi Kawamura; Senji Hoshi; Masanori Ishida; Toshiaki Kawaguchi; Shigeto Ishidoya; Jiro Shimoda; Hiromi Sato; Koji Mitsuzuka; Tatsuo Tochigi; Norihiko Tsuchiya; Chikara Ohyama; Yoichi Arai; Kengo Nagashima; Tomonori Habuchi
Journal:  Cancer Med       Date:  2019-09-11       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.